ArticleEClinicalMedicine2026

Iparomlimab and tuvonralimab (QL1706) combined definitive chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma (QL1706-IIT-02): a single arm, phase 2 trial.

Wencheng Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.